My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 100

    1.

    Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes.

    Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, Kong AP, Ozaki R, Yeung CY, Xu G, Tong PC, Chan JC.

    Diabetes. 2009 Jul;58(7):1518-25. Epub 2009 Apr 28.PMID: 19401427 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry.

    Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW, Ho CS, Chow CC, Tong PC, Chan JC; Hong Kong Diabetes Registry.

    Diabetes Care. 2008 Dec;31(12):2294-300. Epub 2008 Sep 22.PMID: 18809627 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

    Yang X, So WY, Ma RC, Ko GT, Kong AP, Zhao H, Luk AO, Lam CW, Ho CS, Tong PC, Chan JC.

    Diabetes Care. 2009 Oct;32(10):1826-32. Epub 2009 Jul 10.PMID: 19592629 [PubMed - in process]Related articles

    4.

    Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

    Scheen AJ.

    Drugs. 2004;64(22):2537-65. Review.PMID: 15516153 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

    Weir MR.

    Clin Ther. 2007 Sep;29(9):1803-24. Review.PMID: 18035185 [PubMed - indexed for MEDLINE]Related articles

    6.

    Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.

    Haddad GE, Blackwell K, Bikhazi A.

    Can J Physiol Pharmacol. 2003 Feb;81(2):142-9.PMID: 12710528 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.

    Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK.

    Eur J Med Res. 2005 Apr 20;10(4):161-8.PMID: 15946912 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

    Kidney Int Suppl. 2002 Dec;(82):S47-52.PMID: 12410855 [PubMed - indexed for MEDLINE]Related articles

    9.

    Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

    Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME.

    J Hypertens. 2005 Mar;23(3):463-73. Review.PMID: 15716683 [PubMed - indexed for MEDLINE]Related articles

    10.

    Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study.

    van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH.

    Cancer. 2008 Feb 15;112(4):748-57.PMID: 18181094 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.

    Leung PS.

    Diabet Med. 2007 Feb;24(2):110-6. Review.PMID: 17257271 [PubMed - indexed for MEDLINE]Related articles

    12.

    The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies.

    Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinson-Berka JL.

    Am J Pathol. 2003 Jan;162(1):151-60.PMID: 12507898 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]

    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

    Presse Med. 2002 Nov 9;31(36):1714-20. Review. French. PMID: 12467154 [PubMed - indexed for MEDLINE]Related articles

    14.

    Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?

    Vogt L, Kocks MJ, Laverman GD, Navis G.

    Minerva Med. 2004 Oct;95(5):395-409. Review.PMID: 15467515 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.

    Scheen AJ.

    Diabetes Metab. 2004 Dec;30(6):498-505. Review.PMID: 15671919 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

    Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

    Clin Res Cardiol. 2008 Jul;97(7):418-31. Epub 2008 May 3. Review.PMID: 18454336 [PubMed - indexed for MEDLINE]Related articles

    17.

    Intrarenal renin-angiotensin system contributes to tubular acidification adaptation following uninephrectomy.

    Amorena C, Damasco C, Igarreta P, MacLaughlin M.

    Exp Nephrol. 2001;9(1):60-4.PMID: 11053982 [PubMed - indexed for MEDLINE]Related articles

    18.

    Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.

    Bommer WJ.

    Prev Cardiol. 2008 Fall;11(4):215-22. Review.PMID: 19476574 [PubMed - indexed for MEDLINE]Related articles

    19.

    IGF-I treatment attenuates renal abnormalities induced by neonatal ACE inhibition.

    Nilsson AB, Nitescu N, Chen Y, Guron GS, Marcussen N, Matejka GL, Friberg P.

    Am J Physiol Regul Integr Comp Physiol. 2000 Sep;279(3):R1050-60.PMID: 10956265 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

    Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.PMID: 16330466 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity